The deal covers Circulogene's technology for enriching tumor DNA from small volumes of blood for next-generation sequencing-based analysis.
The company's assay relies on proprietary methods of DNA isolation that enable analysis of cell-free DNA from finger-stick volume blood samples.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.